Who
Eric J. Loumeau
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, AnaptysBio; GC & Chief Compliance Officer, Otonomy; VP, Corporate General Counsel, Hollis Eden Pharmaceuticals Inc /de/.
In numbers
- Trades disclosed
- 129
- Buys
- 0
- Sells
- 24
- Bought
- $0
- Sold
- $5.7M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 13 Feb 2006
- Last trade
- 11 Feb 2026
- Last filed
- 13 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Feb 2026filed 13 Feb 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Code M | $297K10,000 at $29.70 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $540K10,000 at $54.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Code M | $297K10,000 at $29.70 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $540K10,000 at $54.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $99K2,210 at $44.71 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $99K2,210 at $44.71 | filing |
| 7 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Code M | —5,888 | filing |
| 7 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —5,888 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —5,888 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Code M | —5,888 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $91K2,017 at $45.11 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $240K5,281 at $45.38 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $85K1,841 at $46.13 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $24K500 at $47.23 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $91K2,017 at $45.11 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $240K5,281 at $45.38 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $85K1,841 at $46.13 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Sold | $24K500 at $47.23 | filing |
News
Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)ANAB · tickerreport.com · 20 Oct 2026
0 headlines in the last 90 days name Eric J. Loumeau; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.